Pharmaceuticals News

Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of...

Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du...

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of...

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform,...

Calroy releases new research explaining how microcirculation and the endothelial glycocalyx influence blood flow, oxygen delivery, and whole-body vitality.

ProText Mobility Inc. (OTC: TXTM) Updates Shareholders on Strategic Developments, Liquidity, and Stock Purchases

PALO ALTO, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing,...

The SPRINT® PNS System is now covered nationally by Aetna® and recognized as a covered treatment option when medically necessary for certain patients.

Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates.